Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01489176 | Regadenoson Real Time Perfusion Imaging Trial-Optison | PHASE3 | COMPLETED | 50 | — | — | Jul 31, 2012 | Dec 1, 2014 | Oct 8, 2024 | 2 | United States |
Measurements will be analyzed to identify a coronary stenosis \>50% in diameter by quantitative cardiac angiography.
| Arm | Type | Description |
|---|---|---|
| Regadenoson; Optison | EXPERIMENTAL | Use of Regadenoson as the chemical stress agent using Optison as a contrast agent during stress echocardiography. |
| Name | Type | Description |
|---|---|---|
| Regadenoson; Optison | DRUG | A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute. |
Inclusion Criteria: * Male or female. Age ≥ 30 years. * Resting Left Ventricular Ejection Fraction \> 40% using Simpson's biplane measurement. * Scheduled for coronary angiography within 30 days of the Regadenoson stress test. * Negative urine pregnancy test within 2 hours of ultrasound contrast ad...